Orthoillinois — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$43,839	33
2024	Research	$107,872	27
2023	Research	$139,822	16
2022	Research	$1,221	5
2021	Research	$39,631	14
2020	Research	$71,755	23

Breakdown

Who paid Research payments · program years 2020–2025

Janssen Research & Development, LLC $147,611 25 payments
AbbVie, Inc. $111,385 37 payments
Exactech, Inc. $91,166 9 payments
Vericel Corporation $20,396 39 payments
Amgen Inc. $19,231 5 payments
GlaxoSmithKline, LLC. $14,000 2 payments
Anika Therapeutics, Inc. $350 1 payment

Studies the money was for Research payments · program years 2020–2025

A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease $147,611 25 payments
M15-572 $47,889 16 payments
Cr09-005 Equinoxe PMCF $38,061 6 payments
A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) - SELECT - PsA 1 $29,761 10 payments
M16-011 $23,866 7 payments
MACI Multicenter Clinical Outcomes Registry $20,396 39 payments
Ph4 Otezla in oligoarticular PsA (FOREMOST)/KEG $19,231 5 payments
A Phase 4, Multicenter, Prospective, Open-Label Study Describing the E $14,000 2 payments
A Phase 3, Randomized, Double-Blind, Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (KEEPsAKE 1) $9,869 4 payments
A Prospective, Randomized, Active Treatment-controlled, Evaluator-blinded Multicenter Study to Establish the Superiority of Hyalofast With BMAC in the Treatment of Articular Knee Cartilage Defect Lesions in Comparison to Control $350 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.